E Baudin

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. doi request reprint One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma
    Ségolène Hescot
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy and University Paris Sud, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 98:4006-12. 2013
  2. doi request reprint Intervention in gastro-enteropancreatic neuroendocrine tumours
    Eric Baudin
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Best Pract Res Clin Gastroenterol 26:855-65. 2012
  3. ncbi request reprint [Biology and imaging of neuroendocrine tumors]
    Eric Baudin
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy 94805 Villejuif
    Rev Prat 52:268-73. 2002
  4. ncbi request reprint Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma
    E Baudin
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Villejuif
    Ann Oncol 13:1806-9. 2002
  5. doi request reprint Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?
    E Baudin
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Univ Paris Sud, Villejuif, France
    Horm Cancer 2:363-71. 2011
  6. ncbi request reprint Impact of chromogranin A measurement in the work-up of neuroendocrine tumors
    E Baudin
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:S79-82. 2001
  7. ncbi request reprint Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma
    E Baudin
    Service de Medecine Nucleaire, Institut Gustave Roussy, Villejuif, France
    Cancer 92:1385-92. 2001
  8. ncbi request reprint Gastroenteropancreatic endocrine tumors: clinical characterization before therapy
    Eric Baudin
    Service de Medécine Nucléaire et Oncologie Endocrinienne, Institut Gustave Roussy, Villejuif, France
    Nat Clin Pract Endocrinol Metab 3:228-39. 2007
  9. ncbi request reprint Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors
    E Baudin
    Nuclear Medicine, Institut Gustave Roussy, Villejuif, France
    J Clin Endocrinol Metab 84:69-75. 1999
  10. pmc Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours
    E Baudin
    , Institut Gustave Roussy, Villejuif, France
    Br J Cancer 78:1102-7. 1998

Detail Information

Publications84

  1. doi request reprint One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma
    Ségolène Hescot
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy and University Paris Sud, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 98:4006-12. 2013
    ..The natural history of malignant pheochromocytoma or paragangliomas (MPP) remain unknown...
  2. doi request reprint Intervention in gastro-enteropancreatic neuroendocrine tumours
    Eric Baudin
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Best Pract Res Clin Gastroenterol 26:855-65. 2012
    ..In the absence of cure at the metastatic stage, progresses are expected in the recognition of well differentiated NET subgroups that display either excellent or poor prognosis...
  3. ncbi request reprint [Biology and imaging of neuroendocrine tumors]
    Eric Baudin
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy 94805 Villejuif
    Rev Prat 52:268-73. 2002
    ..We review main advances in the biological and morphological work-up of these rare tumours, including the role of chromogranine A measurement and somatostatin receptor scintigraphy...
  4. ncbi request reprint Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma
    E Baudin
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Villejuif
    Ann Oncol 13:1806-9. 2002
    ..Complete responses are rare after medical treatment of adrenocortical tumors. We performed a single center prospective study of the antitumor effect of irinotecan (CPT-11) in patients with metastatic adrenocortical cancer...
  5. doi request reprint Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?
    E Baudin
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Univ Paris Sud, Villejuif, France
    Horm Cancer 2:363-71. 2011
    ..International networks and comprehensive databases gathering clinical and biological data constitute the prerequisites for progress...
  6. ncbi request reprint Impact of chromogranin A measurement in the work-up of neuroendocrine tumors
    E Baudin
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:S79-82. 2001
    ..Both tumor burden and secretory activity should be taken into account when interpreting CgA results...
  7. ncbi request reprint Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma
    E Baudin
    Service de Medecine Nucleaire, Institut Gustave Roussy, Villejuif, France
    Cancer 92:1385-92. 2001
    ....
  8. ncbi request reprint Gastroenteropancreatic endocrine tumors: clinical characterization before therapy
    Eric Baudin
    Service de Medécine Nucléaire et Oncologie Endocrinienne, Institut Gustave Roussy, Villejuif, France
    Nat Clin Pract Endocrinol Metab 3:228-39. 2007
    ..Mastery of several key points analyzed in this Review, to be applied during the diagnostic and prognostic processes, is essential for defining a tailored therapeutic management...
  9. ncbi request reprint Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors
    E Baudin
    Nuclear Medicine, Institut Gustave Roussy, Villejuif, France
    J Clin Endocrinol Metab 84:69-75. 1999
    ..Routine hormonal measurements should depend on the primary site. NSE, 5-HIAA, CT, and alphaGP should be routinely measured in foregut-derived NET; only serum NSE and 5-HIAA measurements are recommended in midgut-derived NET...
  10. pmc Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours
    E Baudin
    , Institut Gustave Roussy, Villejuif, France
    Br J Cancer 78:1102-7. 1998
    ..01). Among six patients with NET followed for 11-37 months, CgA appeared to be a better marker of tumour evolution than NSE. We suggest that CgA ought to be the only general marker screened in NET patients...
  11. ncbi request reprint A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas
    M P Ducreux
    Gastroenterology Unit, Institute Gustave Roussy, Villejuif, France
    Oncology 70:134-40. 2006
    ..Only a few drugs are active in the treatment of well-differentiated endocrine carcinomas (WDEC). We evaluated the combination of the so-called 'de Gramont schedule' and irinotecan in these tumors in a phase II study...
  12. doi request reprint Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 93:3021-8. 2008
    ....
  13. doi request reprint Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, University Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Endocrinol 164:89-94. 2011
    ..To make the specificity of fluorodesoxyglucose ((18)FDG) positron emission tomography (PET) precise, in the follow-up of patients with adrenal cancer...
  14. doi request reprint Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy
    G Hajje
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, University Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Endocrinol 168:113-8. 2013
    ..The aim of this study was to evaluate, in patients with advanced MTC treated with cytotoxic chemotherapy, the relationship between early changes of serum CT or CEA levels and progression-free survival (PFS)...
  15. doi request reprint Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, University Paris Sud XI, 39 rue Camille Desmoulins, Villejuif Cedex, France
    Eur J Endocrinol 162:1147-53. 2010
    ..Peritoneal carcinomatosis (PC) is a rare site of distant metastases in patients with adrenocortical cancer (ACC). One preliminary study suggests an increased risk of PC after laparoscopic adrenalectomy (LA) for ACC...
  16. doi request reprint Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
    D Deandreis
    Department of Nuclear Medicine and Endocrine Oncology, National Institute of Health and Medical Research, Institut Gustave Roussy, France
    Endocr Relat Cancer 18:159-69. 2011
    ..Well-differentiated thyroid cancer presenting histological features such as necrosis and FDG uptake on PET scan should be considered aggressive differentiated cancers...
  17. pmc Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
    E Mitry
    Department of Gastroenterology, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 81:1351-5. 1999
    ..However, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies have to be developed...
  18. doi request reprint Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level
    C Nascimento
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Univ Paris Sud, Villejuif, France
    Endocr Relat Cancer 18:R29-40. 2011
    ..In these patients, repeating TSH-Tg 6-18 months after ablation is not useful. (131)I ablation could be avoided in the absence of N1 and aggressive histological variant...
  19. ncbi request reprint Chemoembolization for liver metastases from medullary thyroid carcinoma
    J Fromigue
    Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 91:2496-9. 2006
    ..Distant metastases are the main cause of cancer-related death. Systemic chemotherapy produces only rare tumor responses. Somatostatin analogs and other available modalities are poorly effective to control symptoms...
  20. ncbi request reprint Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy
    C Durante
    Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 91:2892-9. 2006
    ..The goal of this study was to estimate the cumulative activity of (131)I to be administered to patients with distant metastases from thyroid carcinoma...
  21. ncbi request reprint Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
    T Aparicio
    , Institut Gustave Roussy, 94805, Villejuif, France
    Eur J Cancer 37:1014-9. 2001
    ..A slow tumour growth rate before treatment is predictive of a good response to somatostatin analogues which could be considered an option for first-line treatment...
  22. ncbi request reprint Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 91:920-5. 2006
    ....
  23. doi request reprint Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver
    D Elias
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, Cedex, France
    Eur J Surg Oncol 35:1092-7. 2009
    ..It is an extensive application of the current guidelines...
  24. ncbi request reprint Prognostic factors for chemoembolization in liver metastasis from endocrine tumors
    A Roche
    Department of Interventional Radiology, Institut Gustave Roussy, Villejuif Cedex, France
    Hepatogastroenterology 51:1751-6. 2004
    ..The aims of this study were to assess response rates, evaluate side effects and determine prognostic factors for both response and toxicity in patients with liver metastasis from endocrine tumors treated with chemoembolization...
  25. pmc Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma
    R Bonacci
    Institut Gustave Roussy, Villejuif, France
    Br J Cancer 78:546-9. 1998
    ..Toxic effects were as expected and were non-life-threatening; no treatment interruption was required...
  26. pmc Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma
    L Guignat
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 84:808-12. 2001
    ....
  27. ncbi request reprint Follow-up of thyroid cancer patients with favorable prognostic indicators
    S Leboulleux
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne Institut Gustave Roussy, 94805 Villejuif Cedex, France
    Ann Endocrinol (Paris) 64:64-7. 2003
  28. pmc Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging
    G Pellegriti
    , Institut Gustave Roussy, Villejuif, France
    Br J Cancer 88:1537-42. 2003
    ..01). These results show that postoperative CT level and tumour extension are critical prognostic factors for the identification of patients at a high risk of relapse...
  29. ncbi request reprint Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer
    Claudia Scollo
    Nuclear Medicine, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 88:2070-5. 2003
    ....
  30. ncbi request reprint The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?
    Th Delaunoit
    Department of Gastroenterology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Cancer 40:515-20. 2004
    ..7 months, and suggests that it could be considered as a valid option in first-line therapy...
  31. doi request reprint Endocrine pancreatic tumours: which are the most useful MRI sequences?
    C Caramella
    Department of Radiology, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805, Villejuif Cedex, France
    Eur Radiol 20:2618-27. 2010
    ..To determine magnetic resonance imaging (MRI) signal and enhancement characteristics of endocrine pancreatic tumours (ETPs) and which MR sequences show them most consistently...
  32. doi request reprint Molecular targeted therapies for patients with refractory thyroid cancer
    C Chougnet
    Department of Nuclear Medicine and Endocrine Oncology, Centre de Référence Tumeurs Réfractaires de la Thyroïde, Institut Gustave Roussy and University Paris Sud XI, Villejuif, France
    Clin Oncol (R Coll Radiol) 22:448-55. 2010
    ..In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial...
  33. ncbi request reprint Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment
    Anne Bachelot
    Department of Nuclear Medicine and Endocrine Tumours, Institut Gustave Roussy, Villejuif Cedex, France
    Clin Endocrinol (Oxf) 62:376-9. 2005
    ....
  34. doi request reprint Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment
    Stephane Bonnet
    Department of Oncologic Surgery, Institut Gustave Roussy, Villejuif Cedex, France
    J Clin Endocrinol Metab 94:1162-7. 2009
    ..The aim was to determine the effect of lymph node (LN) staging on the indication for treatment with radioiodine...
  35. ncbi request reprint Radioiodine therapy for papillary and follicular thyroid carcinoma
    Michele Klain
    Department of Nuclear Medicine and Commissariat à l Energie Atomique LRC 29V, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    Eur J Nucl Med Mol Imaging 29:S479-85. 2002
    ..It should be used selectively, i.e. only in those patients for whom a clinical benefit may be expected...
  36. pmc Differential expression of galectin 3 in solid cell nests and C cells of human thyroid
    A Faggiano
    Department of Pathology, Institut Gustave Roussy, F 94805 Villejuif Cedex, France
    J Clin Pathol 56:142-3. 2003
    ..To provide new insights into characterising solid cell nests and gain information that might help distinguish between solid cell nests and C cells...
  37. ncbi request reprint Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course
    S Leboulleux
    Service de Cancérologie Endocrinienne et de Médecine Nucléaire, Institut Gustave Roussy, Villejuif, France
    Cancer 94:44-50. 2002
    ..Multiple endocrine neoplasia type 2B (MEN 2B) is an exceptional syndrome, for which the optimal age of thyroidectomy is poorly established and the course of medullary thyroid carcinoma (MTC) is ill-defined...
  38. doi request reprint Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results
    Thierry de Baere
    Department of Interventional Radiology, Institut Gustave Roussy, rue Camille Desmoulins, Villejuif 94805, France
    J Vasc Interv Radiol 19:855-61. 2008
    ..To evaluate the feasibility, safety, and efficacy of transarterial chemoembolization (TACE) of progressive liver metastases from well differentiated gastroenteropancreatic endocrine (GEP) tumors with drug-eluting beads (DEBs)...
  39. ncbi request reprint Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels
    Anne Laure Giraudet
    Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 92:4185-90. 2007
    ..Because calcitonin level remains elevated after initial treatment in many medullary thyroid carcinoma (MTC) patients without evidence of disease in the usual imaging work-up, there is a need to define optimal imaging procedures...
  40. doi request reprint Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
    Cosimo Durante
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Universite Paris XI, 94805 Villejuif Cedex, France
    Endocr Relat Cancer 16:585-97. 2009
    ..This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials...
  41. ncbi request reprint Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia
    Antongiulio Faggiano
    Department of Pathology, Commissariat à l Energie Atomique LRC29V, Institut Gustave Roussy, F 94805 Villejuif Cedex, France
    Clin Endocrinol (Oxf) 57:813-9. 2002
    ..The reliability of this marker in the differential diagnosis between medullary thyroid carcinoma and C-cell hyperplasia was studied by immunohistochemistry...
  42. ncbi request reprint Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy
    Renaud de Crevoisier
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 60:1137-43. 2004
    ..To analyze a prospective protocol combining surgery, chemotherapy (CT), and hyperfractionated accelerated radiotherapy (RT) in anaplastic thyroid carcinoma...
  43. ncbi request reprint Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study
    Dominique Elias
    Department of Surgical Oncology, Comprehensive Cancer Center, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Surgery 133:375-82. 2003
    ..However, surveillance alone yields only a 22% 5-year survival when metastases occur. The aim of this study was to determine the results of hepatic and extra hepatic resections and to clarify the indications of surgery...
  44. ncbi request reprint Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis
    Sophie Leboulleux
    Department of Nuclear Medicine and Endocrine Tumors, Institut National de la Santé et de la Recherche Médicale U605, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 90:5723-9. 2005
    ..Initial treatment, performed at the Institut Gustave Roussy between 1987 and 1997, included in all patients a total thyroidectomy with central and ipsilateral en bloc neck dissection followed by radioactive iodine ablation...
  45. doi request reprint [Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies]
    G Malouf
    Departement de Medecine, Faculte de Medecine Paris Sud, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Bull Cancer 96:95-101. 2009
    ..Vandetanib, an inhibitor of RET and VEGFR tyrosine-kinases, is promising in medullary thyroid cancers. Preliminary results of these trials are discussed in this review...
  46. ncbi request reprint Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients
    E Baudin
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France 94805
    J Clin Endocrinol Metab 88:1107-11. 2003
    ..The best PPV is brought by the slope of serum Tg levels...
  47. doi request reprint Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence
    Dana M Hartl
    Department of Otolaryngology Head and Neck Surgery, Institut Gustave Roussy, Villejuif, France
    Ann Surg Oncol 16:2602-8. 2009
    ..Intraoperative localization of these small foci in previously dissected necks is a surgical challenge. We describe a new technique for ultrasound-guided tattooing to facilitate excision...
  48. ncbi request reprint New therapeutic approaches to treat medullary thyroid carcinoma
    Martin Schlumberger
    University Paris Sud 11, Paris, France
    Nat Clin Pract Endocrinol Metab 4:22-32. 2008
    ..Although RET mutations are common in hereditary MTC and can occur in some cases of sporadic MTC, knowledge of other molecular defects associated with the development of MTC should reveal new targets for therapy...
  49. ncbi request reprint [Imaging strategy for staging and follow-up of endocrine tumors]
    Clarisse Dromain
    Departement de Radiologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex
    Bull Cancer 93:1183-9. 2006
    ..Then we review for each endocrine tumour localization and clinical presentation, the imaging strategy as well as the most common morphological and functional features...
  50. ncbi request reprint [Treatment strategy of neuroendocrine tumors]
    Michel Ducreux
    Unité de gastroentérologie Institut Gustave Roussy 94805 Villejuif
    Rev Prat 52:290-6. 2002
    ..Gastrinoma and other pancreatic tumours arising in the context of multiple endocrine neoplasia type I disease need a specific therapeutic strategy...
  51. doi request reprint Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think
    Dominique Elias
    Department of Oncologic Surgery, Institut Gustave Roussy, Cancer Center, Villejuif, France
    Ann Surg 251:307-10. 2010
    ....
  52. ncbi request reprint Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors
    Alain Roche
    Service de Radiologie Interventionnelle, Institut Gustave Roussy, rue Camille Desmoulins 39, 94805 Villejuif Cedex, France
    Eur Radiol 13:136-40. 2003
    ..Long-term palliation is possible in unresectable liver metastases from digestive neuroendocrine tumors with a few sessions of TACE as first-line and eventually exclusive treatment...
  53. ncbi request reprint Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas
    Dominique Elias
    Division of Surgical Oncology, Department of Surgery, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Surgery 137:411-6. 2005
    ..This study was aimed at assessing the actual prognostic impact of PC and to evaluate a new treatment with respect to survival times...
  54. ncbi request reprint Clinical review: Current concepts in the management of unilateral recurrent laryngeal nerve paralysis after thyroid surgery
    Dana M Hartl
    Department of Otolaryngology and Head and Neck Surgery, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 90:3084-8. 2005
    ..This study was designed to provide an update on the pathophysiological concepts and patient management in a common complication of thyroid surgery, unilateral recurrent laryngeal nerve paralysis (URLNP)...
  55. ncbi request reprint Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging
    Clarisse Dromain
    Department of Radiology, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 23:70-8. 2005
    ..To define predictive factors for "high-sensitivity SRS."..
  56. ncbi request reprint Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer
    Sophie Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 92:3590-4. 2007
    ..Neck ultrasonography (US) has become a keystone in the follow-up of patients with differentiated thyroid cancer...
  57. ncbi request reprint [Endocrine pancreas]
    C Dromain
    Département d Imagerie Médicale, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex
    J Radiol 86:797-804; quiz 805. 2005
    ..The imaging of PET is multidisciplinary with the association of morphological imaging (CT and MRI), endoscopic imaging (endoscopic US) and metabolic imaging (somatostatin receptor scintigraphy and PET-imaging)...
  58. ncbi request reprint [Clinical cases: a well-differentiated endocrine tumor]
    Michel Ducreux
    Departement de Medecine, Service de cancérologie digestive, Institut Gustave Roussy, Villejuif
    Gastroenterol Clin Biol 30:292-4. 2006
  59. doi request reprint Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma
    Eric Baudin
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Villejuif, France
    Am J Clin Oncol 33:83-8. 2010
    ..v.) infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma (MTC)...
  60. doi request reprint Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma
    Pasqualino Malandrino
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Universite Paris XI, 39 rue Camille Desmoulins, Villejuif Cedex, France
    Endocr Relat Cancer 17:797-807. 2010
    ..03 and <0.001). Our study suggests a prognostic role for mitotane therapy and objective response to platinum-based chemotherapy...
  61. ncbi request reprint Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma
    Anne Bachelot
    Institut Gustave Roussy, Villejuif, France
    Thyroid 12:707-11. 2002
    ..Nevertheless, undetectable serum Tg should not be considered as a reliable criteria to exclude a minimal tumor burden in patients who have already been treated with (131)I...
  62. ncbi request reprint Medullary thyroid carcinoma
    Sophie Leboulleux
    Institut Gustave Roussy, Villejuif, France
    Clin Endocrinol (Oxf) 61:299-310. 2004
    ..However, there is no effective treatment for distant metastases, and new therapeutic modalities are urgently needed...
  63. ncbi request reprint Thermal ablation techniques: a curative treatment of bone metastases in selected patients?
    F Deschamps
    Department of Interventional Radiology, Gustave Roussy, 114 rue Edouard Vaillant, 94800, Villejuif, France
    Eur Radiol 24:1971-80. 2014
    ..Thermal ablation techniques (radiofrequency-ablation/cryotherapy) can be indicated with a curative intent. The success rate and prognostic factors for complete treatment were analysed...
  64. ncbi request reprint Prognostic parameters of metastatic adrenocortical carcinoma
    Guillaume Assie
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Universite Paris XI, 94800 Villejuif, France
    J Clin Endocrinol Metab 92:148-54. 2007
    ..Prognostic parameters of metastatic adrenocortical carcinoma (ACC) are poorly characterized...
  65. ncbi request reprint Follicular-cell derived thyroid cancer in children
    Sophie Leboulleux
    Service de Medecine Nucleaire, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Cancer 40:1655-9. 2004
    ..Long term prognosis is favorable, but a few deaths have been reported some decades after initial treatment. Adverse prognostic indicators are younger age at discovery and presence of distant metastases...
  66. ncbi request reprint Inheritable forms of medullary thyroid carcinoma
    Anne Bachelot
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France
    Biochimie 84:61-6. 2002
    ..The identification of hereditary MTC has been facilitated in recent years by the direct analysis of the ret proto-oncogene...
  67. ncbi request reprint Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804
    Francesca Lombardo
    Départment de Biologie Clinique and Service de Médecine Nucléaire, Institut Gustave Roussy, Villejuif, France
    J Clin Endocrinol Metab 87:1674-80. 2002
    ..Indeed, our data should be confirmed on a larger series of V804L carriers, but may offer a balanced strategy to keep under control and prevent development of the full disease phenotype...
  68. ncbi request reprint Follicular cell-derived thyroid cancer in children
    Sophie Leboulleux
    Institut Gustave Roussy, Villejuif, France
    Horm Res 63:145-51. 2005
    ..The aim of initial treatment should be the total removal of neoplastic foci with a minimal morbidity. Some cancer-related deaths have been reported decades after initial treatment...
  69. ncbi request reprint New therapeutic approaches for metastatic thyroid carcinoma
    Eric Baudin
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, and Faculté de Médecine Paris Sud, Villejuif, France
    Lancet Oncol 8:148-56. 2007
    ..However, the recent availability of molecularly targeted treatments has led to changes in the treatment strategy for DTC in patients with distant metastases, especially in those who are resistant to radioiodine treatment...
  70. ncbi request reprint Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features
    Antongiulio Faggiano
    Department of Nuclear Medicine and Endocrinological Oncology, Gustave Roussy Institute, Villejuif, France
    Cancer 110:265-74. 2007
    ..The objective of this study was to investigate the epidemiology, clinical presentation, prognostic factors, and molecular pathways of patients with poorly differentiated LCNEC...
  71. doi request reprint Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging
    Ronan Abgral
    Department of Nuclear Medicine, University Hospital of Brest, 29200 Brest, France
    J Clin Endocrinol Metab 96:665-71. 2011
    ....
  72. ncbi request reprint Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results
    Antongiulio Faggiano
    Department of Nuclear Medicine and Endocrinological Oncology, Gustave Roussy Institute, Villejuif, France
    Clin Endocrinol (Oxf) 64:110-3. 2006
    ..It has been reported that the therapeutic threshold of mitotane, plasma level above 14 microg/ml, is achieved within 3-5 months after o,p'DDD treatment initiation in patients with adrenocortical carcinoma (ACC)...
  73. ncbi request reprint MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques
    Clarisse Dromain
    Department of Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    AJR Am J Roentgenol 180:121-8. 2003
    ..The aim of our prospective study was to assess the MR imaging characteristics of hepatic metastases of neuroendocrine tumors and to determine the optimal MR sequence for their detection...
  74. ncbi request reprint Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma
    Maxime Lamarre-Cliche
    Clinical Investigation Center 9201, Assistance Publique des Hôpitaux de Paris INSERM, Paris, France
    Clin Endocrinol (Oxf) 57:629-34. 2002
    ..We carried out a prospective study on 10 patients with malignant or recurrent phaeochromocytomas to examine the clinical and hormonal effects of three monthly intramuscular injections of 20 mg slow-release octreotide...
  75. ncbi request reprint Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1
    Laurence Thomas-Marques
    Gastroenterology, Hopital Robert Debre, CHU de Reims, France
    Am J Gastroenterol 101:266-73. 2006
    ..The frequency of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1 (MEN1) remains unknown...
  76. ncbi request reprint Digestive endocrine tumors
    Guillaume Cadiot
    Service d Hepato Gastroenterologie, Hopital Robert Debre, Reims
    Gastroenterol Clin Biol 30:2S91-2S97. 2006
  77. doi request reprint Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic features
    Olivier Corcos
    Pôle des Maladies de l Appareil Digestif, AP HP, Hopital Beaujon, Clichy, Paris, France
    Pancreas 37:85-93. 2008
    ..We aimed to assess (1) the accuracy of somatostatin receptor scintigraphy, (2) histological features with focus on malignancy and genotype-phenotype correlations, and (3) prognosis of VHL-EPT...
  78. ncbi request reprint Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy
    Florence de Fraipont
    Institut National de la Sante et de la Recherche Medicale, Equipe Mixte 01 05, Department of Cellular Responses and Dynamics, Angiogenesis Laboratory, Commissariat a l Energie Atomique Grenoble, 17 rue des Martyrs, F 38054 Grenoble Cedex 9, France
    J Clin Endocrinol Metab 90:1819-29. 2005
    ....
  79. doi request reprint Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times
    Anne Laure Giraudet
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy and University Paris Sud, 94805 Villejuif Cedex, France
    Eur J Endocrinol 158:239-46. 2008
    ..The progression of medullary thyroid cancer is difficult to assess with imaging modalities; we studied the interest of calcitonin and carcinoembryonic antigen (CEA) doubling times and of Ki-67 labeling and mitotic index (MI)...
  80. ncbi request reprint Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas
    Laurence Amar
    Hypertension Unit, Hopital Europeen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France
    J Clin Endocrinol Metab 92:3822-8. 2007
    ..Pheochromocytomas and paragangliomas may be malignant either at presentation or during recurrence, but the clinical course of malignant tumors is unpredictable...
  81. ncbi request reprint Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD
    Barbara Pasini
    Department of Genetics, Biology and Biochemistry, University of Torino, Turin, Italy
    Eur J Hum Genet 16:79-88. 2008
    ..We conclude that succinate dehydrogenase deficiency may be the cause of a subgroup of GISTs and this offers a therapeutic target for GISTs that may not respond to STI571 and its analogs...
  82. ncbi request reprint Hyperandrogenism in a postmenopausal woman presenting with a metastatic ileum endocrine tumor
    Anne Bachelot
    Department of Endocrinology and Reproductive Medicine, Hopital Necker, Paris, France
    Fertil Steril 81:675-8. 2004
    ..To elucidate the mechanism of the hyperandrogenism found in a postmenopausal woman presenting an ileum endocrine tumor with ovarian metastases...
  83. ncbi request reprint Chromogranin A as serum marker of pituitary adenomas
    Ilinca Lucia Gussi
    Service d endocrinologie et des maladies de la reproduction, Centre Hospitalier Universitaire Bicêtre, Assistance Publique Hôpitaux de Paris and Faculté de Médecine Paris Sud, Universite Paris XI, Le Kremlin Bicetre, France
    Clin Endocrinol (Oxf) 59:644-8. 2003
    ....
  84. ncbi request reprint Genetic testing in pheochromocytoma or functional paraganglioma
    Laurence Amar
    Universite Paris Descartes, Faculte de Medecine, France
    J Clin Oncol 23:8812-8. 2005
    ..To assess the yield and the clinical value of systematic screening of susceptibility genes for patients with pheochromocytoma (pheo) or functional paraganglioma (pgl)...